

May 24, 2025

The Manager, Listing Department
The National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051
NSE Symbol: PANACEABIO

BSE Limited
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001
BSE Scrip Code: 531349

Reg.: Board Meeting on May 30, 2025, to approve Standalone and Consolidated Audited Financial Results for Quarter and Financial Year ended March 31, 2025

Dear Sir,

Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations"), this is to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Friday, May 30, 2025, at New Delhi, inter-alia, to consider and approve the Audited Financial Results for the Quarter and Financial Year ended March 31, 2025.

In the said meeting, the Board may also consider the matter relating to passing over of dividend on equity as well as preference shares for the said Financial Year.

Further, pursuant to Regulation 46(2) of the SEBI LODR Regulations, notice of the said meeting is also being uploaded on the website of the Company.

With reference to our earlier announcement dated March 26, 2025 intimating the Closure of Trading Window pursuant to the Company's Code of Conduct for Prevention of Insider Trading framed in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time, the trading window of the Company shall remain closed for all Designated Persons of the Company till June 01, 2025 and the same will re-open from June 02, 2025.

This is for your kind information and record please.

Thanking you,
Sincerely yours,

For **Panacea Biotec Limited**

Vinod Goel
Group CFO and Head Legal
& Company Secretary